Equol but not genistein improves early metaphyseal fracture healing in osteoporotic rats

Planta Medica

Volumn 75, Issue 5, 2009, Pages 459-465

  Kolios, Leila ^a   Sehmisch, Stephan ^a   Daub, Florian ^a   Rack, Thomas ^a   Tezval, Mohammed ^a   Stuermer, Klaus Michael ^a   Stuermer, Ewa Klara ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Equol; Estrogen; Fracture healing; Genistein; Osteoporosis; Phytoestrogen

Indexed keywords

EQUOL; ESTRADIOL; ESTROGEN RECEPTOR BETA; GENISTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; CALLUS; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ESTROGEN ACTIVITY; FEMALE; FLUOROCHROME STAINING; FRACTURE HEALING; FRAGILITY FRACTURE; METAPHYSIS; MICRORADIOGRAPHY; NONHUMAN; OSTEOPOROSIS; OSTEOSYNTHESIS; OVARIECTOMY; POSTMENOPAUSE; RAT; TIBIA OSTEOTOMY; TRABECULAR BONE;

ANIMALS; BONY CALLUS; DISEASE MODELS, ANIMAL; ELASTICITY; ESTRADIOL; ESTROGENS; FEMALE; FRACTURE HEALING; GENISTEIN; ISOFLAVONES; OSTEOCLASTS; OSTEOPOROSIS; OVARIECTOMY; PHYTOESTROGENS; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; SOYBEANS; TIBIA;

RATTUS;

EID: 68949149914     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0029-1185380     Document Type: Article

References (28)

1. Savoca S, D'Agosta S, Lombardo G. Evaluation of the hematochemical parameters and bone mineral density of women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and surgical menopause treated with estrogen replacement. Part II. Minerva Ginecol 2007; 59: 215-222 (Pubitemid 47203884)
2. Boonen S, Marin F, Obermayer-Pietsch B, Simoes ME, Barker C, Glass EV, Hadji P, Lyritis G, Oertel H, Nickelsen T, McCloskey EV; EUROFORS Investigators. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008; 93: 852-860
3. Lill CA, Gerlach UV, Eckhardt C, Goldhahn J, Schneider E. Bone changes due to glucocorticoid application in an ovariectomized animal model for fracture treatment in osteoporosis. Osteoporos Int 2002; 13: 407-414 (Pubitemid 34625398)
4. McCann RM, Colleary G, Geddis C, Clarke SA, Jordan GR, Dickson GR, Marsh D. Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. J Orthop Res 2008; 26: 384-393
5. Tarakida A, Higuchi T, Mizunuma H. Evidence of hormone replacement therapy for osteoporosis. Maturitas Epub 2007; PMID: 18830040
6. Horwitz KB. The year in basic science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. Mol Endocrinol Epub ahead of print 2008; PMID: 18845670
7. Beral V. Breast cancer and hormone-replacement therapy in the MillionWomen Study. Lancet 2003; 362: 419-427 (Pubitemid 36999703)
8. Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from theWomen's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333
9. Gustafsson J-A. Estrogen receptor β - a new dimension in estrogen mechanism of action. J Endocrinol 1999; 163: 379-383 (Pubitemid 30033732)
10. Mathey J,Mardon J, Fokialakis N, Puel C, Kati-Coulibali S,Mitakou S, Bennetau- Pelissero C, Lamothe V, Davicco MJ, Lebecque P, Horcajada MN, Coxam V. Modulation of soy isoflavones bioavailability and subsequent effects on bone health in ovariectomized rats: the case for equol. Osteoporos Int 2007; 18: 671-679 (Pubitemid 46525554)
11. Picherit C, Coxam V, Benneteau-Pelissero C, Kati-Coulibali S, Davicco MJ Lebecque E, Barlet JP. Daidzein is more efficient than genistein in preventing ovariectomy-induced bone loss in rats. J Nutr 2000; 130: 1675-1681 (Pubitemid 30451052)
12. Sehmisch S, Hammer F, Christoffel J, Seidlova-Wuttke D, Tezval M, Wuttke W, Stuermer KM, Stuermer EK. Using the biomechanical properties of bone to compare genistein, resveratrol and 8-prenylaringenin as agent for preventing osteoporosis. Planta Med 2008; 74: 794-801
13. Gao YH, Yamagushi M. Suppressive effect of genistein on rat bone osteoclasts: involvement of protein kinase inhibition and protein tyrosine phosphatase activation. Int J Mol Med 2000; 5: 261-267
14. Yokohama S, Suzuki T. Isolation and characterization of a novel equolproducing bacterium from human feces. Biosci Biotechnol Biochem 2008; 72: 2660-2666
15. Setchell KD, Clerici C, Lephart ED. S-equol. A potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr 2005; 81: 1072-1079
16. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood) 2005; 230: 155-170 (Pubitemid 40293689)
17. Stuermer EK, Sehmisch S, Rack T, Seidlova-Wuttke D, Tezval M, Wuttke W, Frosch KH, Stuermer KM. Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. A new fracture- healing model at the tibia in rat. Lang Arch Surg published online 02 December 2008; PMID: 19048282
18. Seidlova-Wuttke D, Hesse O, Jarry H, Christoffel V, Spengler B, Becker T, Wuttke W. Evidence for selective estrogen receptor modulator activity in a black cohosh (Cimifuga racemosa) extract: comparison with estradiol- 17β. Eur J Endocrinol 2003; 149: 336-351 (Pubitemid 37304707)
19. Stürmer EK, Seidlova-Wuttke D, Sehmisch S, Rack T, Wille J, Frosch KH, Wuttke W, Stürmer KM. Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene. J Bone Miner Res 2006; 21: 89-96
20. Schenk RK. The histological preparation of undecalcified bone. Acta Anat 1965; 60: 3-19
21. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987; 2: 595-610
22. Cao Y, Mori S, Mashiba T,Westmoore MS, Ma L, Sato M, Akiyama T, Shi L, Komatsubara S, Miyamoto K, Norimatsu H. Raloxifene, estrogen and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res 2002; 17: 2237-2246 (Pubitemid 35416758)
23. Schmidmaier G, Wildemann B, Bail H, Lucke M, Fuchs T, Stemberger A, Flyvberg A, Haas NP, Raschke M. Local application of growth factors (insulin- like growth factor-1 and transforming growth factor-β) from a biodegradable poly (D,L-lactide) coating of osteosynthetic implants accelerated fracture healing in rats. Bone 2001; 28: 341-350 (Pubitemid 32390106)
24. Wronski TJ, Yen CF. The ovariectomized rat as an animalmodel for postmenopausal bone loss. Cells Mater Suppl 1991; 1: 69-74
25. Setchell KD, Cole SJ. Method of defining equol-producer status and its frequency among vegetarians. J Nutr 2006; 136: 2188-2193
26. Yamagishi T, Otsuka E, Hagiwara H. Reciprocal control of expression of mRNAs for osteoclast differentiation factor and OPG in osteogenic stromal cells by genistein: evidence for the involvement of topoisomerase II in osteoclastogenesis. Endocrinology 2001; 142: 3632-3637 (Pubitemid 32681774)
27. Rachon D, Seidlova-Wuttke D, Vortherms T, Wuttke W. Effects of dietary equol on body weight gain, intra-abdominal fat accumulation, plasma lipids, and glucose tolerance in ovariectomized Sprague-Dawley rats. Menopause 2007; 14: 925-932 (Pubitemid 47517594)
28. Rachon D, Vortherms T, Seidlova-Wuttke D,Wuttke W. Effects of dietary equol administration on ovariectomy induced bone loss in Sprague-Dawley rats. Clin Calcium 2008; 18: 1434-1441